drugset / Trial / NCT02342600
SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the combination of trametinib and pazopanib in patients with advanced gastrointestinal stromal tumors (GIST).
Timeline
- Start
- 2017-01
- Primary completion
- 2020-01
- Completion
- —
Outcome
Outcome not reported
Stopped: “Supporting company withdrew interest”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pazopanib | Small molecule | 800 mg | Oral |
| Subject | Trametinib | Small molecule | 2 mg | Oral |